2026-06-06T04:01:00Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/317622026-02-03T11:34:54Zcom_10630_2254col_10630_37953

00925njm 22002777a 4500 dc Arasi, Stefania author Caubet, J.C. author Ceylan, Ozlem author Ibon Eguíluz, Gracia author Giacco, Stefano Del author Gelincik, Asli author Jute, Marek author Rosan, Meyer author Ollert, Markus author Torres-Jaén, María Josefa author 2024-05 Breastmilk is the optimal source of nutrition for infants and should ideally be provided exclusively for the first 6 months of life, and alongside complementary food until 2 years of life. However, there are circumstances where a breastmilk substitute (BMS) may be required. This includes maternal and/or child conditions or personal preference. Whilst these circumstances should never be used as an opportunity to promote BMS, healthcare professionals (HCPs) need to have the knowledge of suitable alternatives and should always be guided by scientific and health motives when recommending a BMS. The Task Force ‘Milk Formula Industry Sponsorship’ from the European Academy of Allergy and Clinical Immunology (EAACI), provides with this publication recommendations for EAACI interactions with the BMS manufacturers and how this will be supervised. Arasi S, Caubet J-C, Ceylan O, et al. Working with companies that manufacture breastmilk substitutes: An EAACI position paper. Pediatr Allergy Immunol. 2024; 0:e14142. https://hdl.handle.net/10630/31762 10.1111/pai.14142 Leche materna Alergia Working with companies that manufacture breastmilk substitutes: An EAACI position paper